Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

158.49B

Market cap158.49B

Price-Earnings ratio

17.40

Price-Earnings ratio17.40

Dividend yield

2.49%

Dividend yield2.49%

Average volume

9.45M

Average volume9.45M

High today

$128.70

High today$128.70

Low today

$124.38

Low today$124.38

Open price

$125.47

Open price$125.47

Volume

19.91M

Volume19.91M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$106.84

52 Week low$106.84

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $127.51, giving the company a market capitalization of 158.49B. It carries a P/E multiple of 17.40 and pays a dividend yield of 2.49%.

During the trading session on 2026-06-29, Gilead Sciences(GILD) shares reached a daily high of $128.70 and a low of $124.38. At a current price of $127.51, the stock is +2.5% higher than the low and still -0.9% under the high.

Trading activity shows a volume of 19.91M, compared to an average daily volume of 9.45M.

The stock's 52-week range extends from a low of $106.84 to a high of $157.29.

GILD News

Simply Wall St 1d

How Trodelvy’s New First-Line Breast Cancer Role Could Reframe Gilead Sciences’ Investment Narrative

Earlier this week, Gilead Sciences reported that regulators in the US and Europe approved expanded first-line use of Trodelvy for unresectable locally advanced...

Simply Wall St 2d

Gilead Wins FDA Approval For Trodelvy In First Line Triple Negative Breast Cancer

Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy as a first-line treatment for adult patients with advanced or metastatic triple-negative brea...

TipRanks 6d

Gilead announces EC grants marketing authorization for Trodelvy

Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy as monotherapy for the treatment of adult patient...

Analyst ratings

79%

of 29 ratings

Buy

79.3%

Hold

20.7%

Sell

More GILD News

Investing.com 6d

Gilead’s Trodelvy wins EU approval for first-line breast cancer - Investing.com

...

Simply Wall St 7d

Gilead Sciences Stock Could Be 3.6% Undervalued After FDA Filing And Phase 3 HIV Data

Gilead Sciences (GILD) is back in focus after the FDA accepted its supplemental filing for a once-weekly oral Yeztugo tablet for HIV prevention, alongside posit...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.